Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apogee Therapeutics, Inc. (APGE) SEC filings page on Stock Titan aggregates the company’s U.S. Securities and Exchange Commission disclosures, providing insight into its status as a Nasdaq-listed, clinical-stage biotechnology issuer. These documents include current reports on Form 8-K, financial statements, equity offering details and other regulatory information that frame Apogee’s development and financing activities in inflammatory and immunology (I&I) therapeutics.
Apogee’s Forms 8-K illustrate how the company reports material events such as quarterly financial results, interim clinical data for programs like APG777 and APG333, and the terms of underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement. Selected 8-Ks also summarize outcomes of the annual meeting of stockholders, including director elections, auditor ratification and advisory votes on executive compensation frequency.
Through these filings, investors can review Apogee’s reported research and development and general and administrative expenses, net losses, cash and marketable securities balances, and the impact of capital raises on its operating runway. Offering-related filings describe underwriting agreements, option exercises by underwriters, pre-funded warrant terms and associated legal opinions, all of which help clarify the structure of Apogee’s capital formation.
On Stock Titan, users can access Apogee’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents such as earnings-related 8-Ks and registration statement updates. This includes highlighting where the company discusses clinical trial timelines, interim data disclosures, and other items relevant to its I&I pipeline. The filings page also surfaces exhibits like press releases and data presentations incorporated into 8-Ks, as well as cover page information confirming that Apogee’s common stock trades on The Nasdaq Global Market under the symbol APGE.
For those monitoring regulatory developments, capital structure changes or disclosure around programs such as APG777, APG279 and APG333, the SEC filings page offers an organized view of Apogee’s official communications with regulators and investors.
Apogee Therapeutics (APGE) filed an 8-K to disclose positive 16-week data from Part A of its Phase 2 APEX trial evaluating APG777, an anti-IL-13 antibody, in moderate-to-severe atopic dermatitis (AD). The randomized, placebo-controlled study (n = 123; 2:1 randomization) met its primary endpoint, delivering a 71.0% mean EASI score reduction versus 33.8% for placebo. Key secondary endpoints also favored APG777, with EASI-75 achieved by 66.9% of treated patients (24.6% placebo) and EASI-90 by 33.9% (14.7% placebo). Exposure-response analyses showed up to 89.5% EASI-75 in the highest drug-exposure quartile.
Safety appeared benign: TEAEs occurred in 56.1% of treated subjects versus 63.4% placebo, serious TEAEs were 1.2% vs 2.4%, and no injection-site reactions were reported. Common events—non-infective conjunctivitis, URTI, nasopharyngitis—were comparable or lower than placebo.
Next steps: Part B (≈280 pts, four-arm dose optimisation) is enrolling with 16-week data expected mid-2026, enabling a planned Phase 3 start in 2026. Maintenance data (3-/6-month dosing) from Part A are due 1H 2026. A separate Phase 1b head-to-head trial of APG279 versus Dupixent has begun, with readout 2H 2026.
The company will host a conference call on 7 July 2025 at 8:00 a.m. ET to review results. Exhibits 99.1 and 99.2 contain the full press release and deck; they are furnished, not filed.
Apogee Therapeutics (APGE) reported insider stock option grants to directors affiliated with Fairmount Funds Management. On June 17, 2025, two directors received identical stock option packages:
- Peter Harwin and Tomas Kiselak each received options to purchase 14,461 shares at an exercise price of $41.66 per share
- Options will vest on the one-year anniversary of the grant date (June 17, 2026)
- Options expire on June 17, 2035
Both directors hold these options on behalf of Fairmount Funds Management investment vehicles and must turn over any proceeds to Fairmount. Both directors disclaim beneficial ownership except for their pecuniary interest. Fairmount is deemed a director by deputization due to Harwin and Kiselak serving as both board members and Managing Members of Fairmount.
Apogee Therapeutics, Inc. (APGE) – Form 4 insider filing
On 17 June 2025, director Nimish P. Shah received a new stock-option grant covering 14,461 common shares. The option has an exercise price of $41.66, a 10-year term expiring 17 June 2035, and vests in full on the first anniversary of the grant date, contingent on continued service.
The filing lists the transaction as code “A” (acquired), indicating it is an original award rather than a market purchase. No non-derivative share transactions were reported, so Mr. Shah’s direct common-stock position is unchanged.
According to a pre-existing agreement, the option is deemed to be held for the sole benefit of VR Management, LLC. Consequently, both the reporting person and VR Management may be considered indirect beneficial owners. Mr. Shah disclaims beneficial ownership beyond any pecuniary interest.
- No cash consideration was paid for the option (price of derivative security reported as $0.00).
- Ownership is reported as Direct (D), subject to the indirect-beneficial-ownership disclaimer above.
The grant represents normal director compensation and does not, by itself, alter Apogee’s capital structure or have an immediate cash impact. Investor takeaway: routine alignment of director incentives with shareholder value; no material operational or financial effect.
Apogee Therapeutics director Mark C. McKenna received a stock option grant on June 17, 2025, according to a Form 4 filing. The derivative securities transaction details include:
- Granted 14,461 stock options to purchase common stock
- Exercise price set at $41.66 per share
- Options will vest fully on the one-year anniversary of the grant date (June 17, 2026)
- Options expire on June 17, 2035
- Vesting is contingent on continued service with the company
The transaction represents a standard director compensation equity grant. The filing was signed by Matthew Batters as attorney-in-fact for McKenna on June 20, 2025. McKenna holds these options under direct ownership.
Apogee Therapeutics (APGE) filed a Form 4 disclosing that director William A. Jones Jr. received a grant of 14,461 non-qualified stock options on 17 June 2025. The options carry an exercise price of $41.66 and expire on 17 June 2035. According to the filing, the award vests 100 % on the first anniversary of the grant date, contingent upon Mr. Jones’ continued service. The transaction increases his derivative holdings to 14,461 options; there was no concurrent acquisition or disposition of common shares. Because this is a routine director equity grant with no immediate cash outlay, it does not directly affect Apogee’s share count, earnings or cash flow, but it modestly aligns the director’s incentives with future shareholder value.